In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine

Roger Paredes, Manish Sagar, Vincent C. Marconi, Rebecca Hoh, Jeffrey N. Martin, Neil T. Parkin, Christos J. Petropoulos, Steven G. Deeks, Daniel R. Kuritzkes

    Research output: Contribution to journalArticleResearchpeer-review

    64 Citations (Scopus)

    Abstract

    Lamivudine therapy selects for the M184V mutation. Although this mutation reduces the replicative capacity of human immunodeficiency virus in vitro, its impact on viral fitness in vivo has not been well defined. We used quantitative allele-specific PCR to precisely calculate the fitness differences between the mutated M184V virus and one that had reverted to the wild type in a cohort of patients by selectively interrupting reverse transcriptase inhibitor therapy, and we found that the M184V variants were consistently 4 to 8% less fit than the wild type in the absence of drug. After a lag phase of variable duration, wild-type variants emerged due to continued evolution of pol and back mutation rather than through emergence of an archived wild-type variant. Copyright © 2009, American Society for Microbiology. All Rights Reserved.
    Original languageEnglish
    Pages (from-to)2038-2043
    JournalJournal of Virology
    Volume83
    Issue number4
    DOIs
    Publication statusPublished - 1 Feb 2009

    Fingerprint Dive into the research topics of 'In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine'. Together they form a unique fingerprint.

  • Cite this

    Paredes, R., Sagar, M., Marconi, V. C., Hoh, R., Martin, J. N., Parkin, N. T., Petropoulos, C. J., Deeks, S. G., & Kuritzkes, D. R. (2009). In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. Journal of Virology, 83(4), 2038-2043. https://doi.org/10.1128/JVI.02154-08